1. Home
  2. ANIX vs LANV Comparison

ANIX vs LANV Comparison

Compare ANIX & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.49

Market Cap

119.8M

Sector

Health Care

ML Signal

HOLD

Logo Lanvin Group Holdings Limited

LANV

Lanvin Group Holdings Limited

HOLD

Current Price

$1.00

Market Cap

131.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
LANV
Founded
1982
2015
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
131.0M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
ANIX
LANV
Price
$3.49
$1.00
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
209.9K
69.3K
Earning Date
05-27-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
N/A
EPS
N/A
N/A
Revenue
$210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$1.00
52 Week High
$5.46
$2.40

Technical Indicators

Market Signals
Indicator
ANIX
LANV
Relative Strength Index (RSI) 58.73 38.88
Support Level $2.73 N/A
Resistance Level $3.89 $1.79
Average True Range (ATR) 0.20 0.08
MACD 0.01 0.00
Stochastic Oscillator 69.92 13.64

Price Performance

Historical Comparison
ANIX
LANV

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.

Share on Social Networks: